Moderna Surge Inflicts $5.5 Billion Short Loss
Moderna shares jumped 177 percent on Wednesday after the company reported positive late-stage data for a personalized melanoma vaccine developed with
Needham
Every Fin-node story mentioning Needham — 1 story, newest first.
Needham · 1 story